Dana Farber Partners Can Ctr

Boston, Massachusetts 02115-6084

0 studies enrolling now · 2 studies all time

What they study most

Non-Small Cell Lung Cancer, Sarcoma

Studies at this site

• A Study of R1507 in Participants With Recurrent or Refractory Sarcoma — Stopped early
• Expanded Access Study of Alectinib for Participants With Anaplastic Lymphoma Kinase (ALK)-Rearranged Non-Small Cell Lung Cancer (NSCLC) After Disease Progression on or Intolerance to Prior ALK Tyrosine Kinase Inhibitor Therapy — NO_LONGER_AVAILABLE